Skip to main content

Boosting Novel Therapeutics—PROTAC Discovery Solutions at Creative Biolabs

Creative Biolabs' scientists have always been chasing the frontier technology in the lifescience scope, who are really skilled at the discovery of PROTAC molecules, a novel therapeutics that has gained full attention in the medical field.

Shirley, United States - October 19, 2020 /MarketersMedia/

The COVID-19 is still hurting the world, affecting people's daily life, hindering economic growth, and threatening the medical system of the United States, but the scientists at Creative Biolabs keep to their post, making contributions to discovering a novel therapeutics of protein degraders, proteolysis targeting chimeric (PROTAC) molecules. PROTAC refers to a small molecule that is heterobifunctional, composed of a linker and two warheads, with one binding to the target protein, and the other recruiting the E3 ligase. PROTAC molecule, compared with conventional drugs that inhibit the activity of the disease-causing protein, utilizes the proteasome-mediated proteolysis via E3 ligase and engages the body's protein degradation system to selectively degrade the pathogenic proteins, providing a novel approach to cancer treatment that requires low dosage, and is less toxic, but more accurate.

Creative Biolabs launches a series of programs regarding the protac molecule discovery to enable one-stop solution of customers' projects.

Ligand design for target protein & ligand screening for E3 ligase
The specificity and affinity of ligands are crucial for the degradation ability of protac molecules. Creative Biolabs has ligand products for quick delivery. In addition, using the advanced platform, the scientists can design the optimal ligand for interested proteins, covering popular cytosolic/nuclear/trans-membrane targets, transcription factors/kinases/receptors, and even proteins with little reference.

A comprehensive set of ligand screening service for E3 ligase of interest is offered for determining the most efficient PROTAC, including but unrestricted to the Von Hippel-Lindau disease tumor suppressor protein (VHL), the Mouse Double Minute 2 homologue (MDM2), the Cellular Inhibitor of Apoptosis (cIAP), and ereblon (CRBN).

Design and optimization of protac linkers & PROTAC structural modification
The structure of a PROTAC molecule plays an indispensable role in the efficacy, which has a linker connecting the two functional ends, i.e., a ligand for E3 ligase recognition and a ligand for target protein recognition. This program can help manufacture the best-fit linker that is optimal in length and position.

Using the exclusive chemical structural modification platform, the structure of PROTAC can be modified in various factors to achieve desired properties, such as lipophilicity, shape, molecular weight, reactivity, pKa, etc.

Novel therapeutics like PROTAC are promising approaches towards precision medicine that aims at treating disease efficiently, meanwhile reducing damage to normal tissues. As an expert, Creative Biolabs can handle the projects efficiently, with a satisfactory quality of the result. More details are available at https://www.creative-biolabs.com/protac/.

Profile:
Creative Biolabs is a pioneering role in the field of novel therapeutics discovery, which was established in New York in 2004. For over a decade, their scientists and technicians have been exploring the PROTAC molecule drugs and successfully launched a series of services and qualified products to support the research in relevant fields. With the accomplishment of dozens of successful cases, Creative Biolabs has accumulated rich project experience and regular customers.

Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/protac/

Source URL: https://marketersmedia.com/boosting-novel-therapeuticsprotac-discovery-solutions-at-creative-biolabs/88981552

Source: MarketersMedia

Release ID: 88981552

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.